Immuron Share Price and Company Fundamentals
Last traded: 05/26/2021
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.
Key Metrics
PE ratio
-
PB ratio
1.27
Dividend yield
Beta
1.79
Market cap
$35.86M
Enterprise value
$9.98M
Company profile
| Primary activities | Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans relating to gastrointestinal health, liver diseases such as fatty liver/NASH and infectious diseases such as Clostridium diffi |
|---|---|
| Industry / Sector | Biotechnology / Healthcare |
| Website | http://www.immuron.com.au |
| Mailing address | 62 Lygon Street Level 3 Carlton South Carlton VIC 3053 Australia |
| Phone / Fax | 61 3 8892 4802 / 61 3 9899 8533 |
| Share registry | AUTOMIC REGISTRY SERVICES |
Dividends
Immuron does not pay dividends.
Company Executives
As of Aug 2021, following are the company executives and directors listed on Immuron.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Jerry Kanellos Ph.D. | CEO & COO | 59 | 244.54k |
| Mr. Peter Anastasiou | Exec. Vice Chairman | 60 | 37.5k |
| Mr. Phillip Allen Hains | CFO & Company Sec. | 61 | |
| Mr. David Lyon | Head of Marketing | ||
| Dr. Dan Ruben Peres | Chief Medical Officer | 44 |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-653.41%
Return on assets
-21.43%
Return on equity
-40.38%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Immuron is 35.86M and its enterprise value is 9.98M. The enterprise value to revenue ratio of IMC is 10.16.
The IMC's stocks Beta value is 1.79 making it 79% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Immuron (IMC)
Immuron (ASX:IMC) Frequently Asked Questions
1. What is Immuron's Stock Symbol?
Immuron trades on ASX under the ticker symbol "IMC".
2. What is Immuron's stock price today?
One share of IMC stock can currently be purchased for approximately $0.16.
3. How can I contact Immuron?
Immuron's mailing address is 62 Lygon Street Level 3 Carlton South Carlton VIC 3053 Australia. The company can be reached via phone at 61 3 8892 4802.
4. What is Immuron's official website?
The official website of Immuron is http://www.immuron.com.au.
5. Which share registry manages Immuron's stock?
Immuron's stock is managed by AUTOMIC REGISTRY SERVICES.